

**EUROPEAN PATENT APPLICATION**

Application number: 89105501.4

Int. Cl. 4: **A61B 5/00**

Date of filing: 29.03.89

Note:  
 FIG 4 MISSING  
 FROM ALL  
 AVAILABLE VERSION

Priority: 30.03.88 US 175115

Date of publication of application:  
04.10.89 Bulletin 89/40

Designated Contracting States:  
AT BE CH DE FR GB LI LU NL


Applicant: **NELLCOR INCORPORATED**  
 25495 Whitesell Street  
 Hayward California 94545(US)

Inventor: **Stone, Robert T.**  
 1028 Helena Drive  
 Sunnyvale California 94087(US)  
 Inventor: **Briggs, Deborah A.**  
 2426 Talavera Drive  
 San Ramon California 94583(US)

Representative: **Vossius & Partner**  
 Siebertstrasse 4 P.O. Box 86 07 67  
 D-8000 München 86(DE)

Method and apparatus for calculating arterial oxygen saturation based on plethysmographs including transients.

A method and apparatus for improving the calculation of oxygen saturation by non-invasive pulse oximeters during transient conditions. Transient conditions introduce artifactual errors into the detected optical signal because of changes in transmittance of the light with localized blood volume changes and as the average background oxygen saturation level of the patient's blood changes. The invention relates to correcting the detected optical pulses by selective frequency filtering and compensating the detected optical signal using the filtered signal to provide accurate estimates of oxygen saturation during transient conditions.



Xerox Copy Centre

# METHOD AND APPARATUS FOR CALCULATING ARTERIAL OXYGEN SATURATION BASED ON PLETHYSMOGRAPHS INCLUDING TRANSIENTS

This invention relates to non-invasive pulse oximetry and specifically to an improved method and apparatus for calculating arterial saturation during transient conditions based upon photoelectric determination of a patient's plethysmograph.

Non-invasive photoelectric pulse oximetry has been previously described in U.S. Patent 4,407,290, U.S. Patent 4,266,554, U.S. Patent 4,086,915, U.S. Patent 3,998,550, U.S. Patent 3,704,708, European Patent Application No. 102,816 published March 13, 1984, European Patent Application No. 104,772 published April 4, 1984, European Patent Application No. 104,771 published April 4, 1984, and PCT International Publication WO 86/05674 published October 9, 1986. Pulse oximeters are commercially available from Nellcor Incorporated, Hayward, California, U.S.A., and are known as, for example, Pulse Oximeter Model N-100 (herein "N-100 oximeter") and Model N-200 (herein "N-200 oximeter").

Pulse oximeters typically measure and display various blood flow characteristics including but not limited to blood oxygen saturation of hemoglobin in arterial blood, volume of individual blood pulsations supplying the flesh, and the rate of blood pulsations corresponding to each heartbeat of the patient. The oximeters pass light through human or animal body tissue where blood perfuses the tissue such as a finger, an ear, the nasal septum or the scalp, and photoelectrically sense the absorption of light in the tissue. The amount of light absorbed is then used to calculate the amount of blood constituent being measured.

The light passed through the tissue is selected to be of one or more wavelengths that is absorbed by the blood in an amount representative of the amount of the blood constituent present in the blood. The amount of transmitted light passed through the tissue will vary in accordance with the changing amount of blood constituent in the tissue and the related light absorption.

For example, the N-100 oximeter is a microprocessor controlled device that measures oxygen saturation of hemoglobin using light from two light emitting diodes ("LED's"), one having a discrete frequency of about 660 nanometers in the red light range and the other having a discrete frequency of about 925 nanometers in the infrared range. The N-100 oximeter microprocessor uses a four-state clock to provide a bipolar drive current for the two LED's so that a positive current pulse drives the infrared LED and a negative current pulse drives the red LED to illuminate alternately the two LED's so that the incident light will pass through, e.g., a fingertip, and the detected or transmitted light will be detected by a single photodetector. The clock uses a high strobing rate, e.g., one thousand five hundred cycles per second, to be easily distinguished from other light sources. The photodetector current changes in response to the red and infrared light transmitted in sequence and is converted to a voltage signal, amplified, and separated by a two-channel synchronous detector -- one channel for processing the red light waveform and the other channel for processing the infrared light waveform. The separated signals are filtered to remove the strobing frequency, electrical noise, and ambient noise and then digitized by an analog to digital converter ("ADC"). As used herein, incident light and transmitted light refers to light generated by the LED or other light source, as distinguished from ambient or environmental light.

The light source intensity may be adjusted to accommodate variations among patients' skin color, flesh thickness, hair, blood, and other variants. The light transmitted is thus modulated by the absorption of light in the variants, particularly the arterial blood pulse or pulsatile component, and is referred to as the plethysmograph waveform, or the optical signal. The digital representation of the optical signal is referred to as the digital optical signal. The portion of the digital optical signal that refers to the pulsatile component is labeled the optical pulse.

The detected digital optical signal is processed by the microprocessor of the N-100 oximeter to analyze and identify optical pulses corresponding to arterial pulses and to develop a history as to pulse periodicity, pulse shape, and determined oxygen saturation. The N-100 oximeter microprocessor decides whether or not to accept a detected pulse as corresponding to an arterial pulse by comparing the detected pulse against the pulse history. To be accepted, a detected pulse must meet certain predetermined criteria, for example, the expected size of the pulse, when the pulse is expected to occur, and the expected ratio of the red light to infrared light of the detected optical pulse in accordance with a desired degree of confidence. Identified individual optical pulses accepted for processing are used to compute the oxygen saturation from the ratio of maximum and minimum pulse levels as seen by the red wavelength compared to the maximum and minimum pulse levels as seen by the infrared wavelength, in accordance with the following equation:

$$\text{Saturation} = 100\% \times \frac{\text{BR2} - \text{R}(\text{BR1})}{\text{R}(\text{BO1} - \text{BR1}) + \text{BR2} - \text{BO2}}$$

5

wherein

BO1 is the extinction coefficient for oxygenated hemoglobin at light wavelength 1 (Infrared)

BO2 is the extinction coefficient for oxygenated hemoglobin at light wavelength 2 (red)

BR1 is the extinction coefficient for reduced hemoglobin at light wavelength 1

10

BR2 is the extinction coefficient for reduced hemoglobin at light wavelength 2

light wavelength 1 is infrared light

light wavelength 2 is red light

and R is the ratio of the optical density of wavelength 2 to wavelength 1 and is calculated as:

15

$$R = \frac{\ln [I_{\max 2} / I_{\min 2}]}{\ln [I_{\max 1} / I_{\min 1}]}$$

20

wherein

$I_{\max 2}$  is the maximum light transmitted at light wavelength 2

$I_{\min 2}$  is the minimum light transmitted at light wavelength 2

$I_{\max 1}$  is the maximum light transmitted at light wavelength 1

$I_{\min 1}$  is the minimum light transmitted at light wavelength 1

25

The various extinction coefficients are determinable by empirical study as are well known to those of skill in the art. For convenience of calculation, the natural log of the ratios may be calculated by use of the Taylor expansion series for the natural log.

Several alternate methods of processing and interpreting optical signal data have been disclosed in the patents and references cited above.

30

Normally, the relative oxygen content of the patient's arterial pulses remains about the same from pulse to pulse and the average background absorption between pulses remains about the same. Consequently, the red and infrared light that is transmitted through the pulsatile flow produces a regularly modulated plethysmograph waveform having periodic optical pulses of comparable shape and amplitude and a steady state background transmittance. This regular pulse provides for an accurate determination of the oxygen saturation of the blood based on the detected relative maximum and minimum transmittance of the red and infrared light.

35

Changes in the patient's local blood volume at the optical detection site affect the absorption of light. These localized changes often result from motion artifact or respiratory artifact which introduce artificial pulses into the blood flow. For example, on each inhalation, the venus return is occluded slightly, which results in the background intensity component of transmittance being decreased due to the relatively larger volume of blood at the optical detection site. Exhalation allows the venus return to expand, thereby decreasing the volume of blood and increasing the background intensity component of transmittance. Consequently, the periodic optical pulses ride on a background intensity component of transmittance that rises and falls with blood volume change. This background intensity component variation, which is not necessarily related to changes in saturation, affects the pulse to pulse uniformity of shape, amplitude and expected ratio of the maximum to minimum transmittance, and can affect the reliability and accuracy of the saturation determination.

45

In addition, there are times when the patient's background level of oxygen saturation undergoes transient changes, for example, when the patient loses or reacquires oxygen exchange in the lungs while under gaseous anesthesia. Consequently, the detected red and infrared light transmittance changes and the detected plethysmograph waveform rises or falls over time with changes in the average oxygen saturation level in the patient's blood. The transient waveform distorts the pulse shape, amplitude, and the expected ratio of the pulses, which in turn affects the reliability and accuracy of the saturation determination.

50

Heretofore, with the foregoing known techniques for calculating arterial oxygen saturation, it was known that, during changes in the background intensity absorption component due to artifacts from changes in the patient's blood volume or transient saturation changes, the determined saturation value was not accurate and that it would not become accurate again until the average absorption (or transmittance) level stabilized at the end of the artifact or the saturation transient.

55

It also was known that saturation calculations based upon transient optical signals provided an over-estimation or under-estimation of the actual saturation value, depending upon the trend. The transmittance of red light near the 660 nanometer wavelength increases as oxygen saturation increases. This results in the detected optical signal value having a smaller pulsatile amplitude, i.e., a smaller relative difference between the maximum and minimum of the pulse. In contrast, the transmittance of the infrared light near the 910 nanometer wavelength decreases as saturation increases, which causes the infrared pulsatile amplitude - relative maximum to minimum - to increase. For both wavelengths, the transmittance changes with changing saturation are substantially linear and continuous in the range of clinical interest, i.e., oxygen saturations between 50% and 100%.

The accuracy of the estimation is of particular concern during rapid desaturation, where average oxygen saturation drops rapidly, but the saturation determination based on the detected optical signals indicates a greater drop than has actually occurred. The determined saturation thus may actuate low limit saturation alarms on an oximeter device that can result in unnecessary and wasteful efforts to resuscitate a patient not in danger.

Applicants believe that the change in transmittance that occurs between the maximum transmittance time and minimum transmittance time is due to the difference in arterial pulsatile length of pulse that has the same oxygen saturation. Because the pulsatile amplitude is quite small, typically less than 5% of the overall intensity change, any small change in overall or background transmittance, such as slight changes in average blood saturation, can have a relatively large effect in the difference in maximum and minimum intensity of the light levels. Because the transmittance effect of changing oxygen saturation is opposite in direction for the red light at 660 nanometers than for infrared light at 910 nanometers, this can result in over-estimation of the pulsatile ratio during periods when saturation is decreasing, and under-estimation during periods when saturation is increasing.

It is therefore an object of this invention to provide a method and apparatus for compensating for the effects of transient conditions in the actual optically detected signal, thereby providing a more accurate estimation of the actual oxygen saturation value.

It is another object of this invention to compensate for the effects of distortion in the detected oxygen saturation signal caused by artifacts due to localized blood volume changes.

It is another object of this invention to compensate for the effects of distortion in the detected oxygen saturation signal caused by transient saturation or blood volume artifact by using the low frequency characteristics of the detected signal values.

This invention provides a method and apparatus for compensating for the artifactual errors in light transmittance during blood volume changes or transient saturation changes (hereinafter collectively referred to as "transient conditions"), thereby providing for improved accuracy of oxygen saturation calculations during transient conditions. The invention provides apparatus for processing the detected optical signals during transient conditions so that the distortion in transmittance caused by the transient can be compensated. In the preferred embodiment, the compensation is made by dividing the detected optical signal by its low frequency components, i.e., the background and transient frequencies below the heart beat frequency, from which quotient signal the compensated maximum and minimum transmittance values can be detected and used in making the saturation determination. Throughout this application, the words compensate, correct and adjust are intended to have the same meaning in that the actual detected value is converted to an artificial value that results in a more accurate estimation of the actual oxygen saturation of the patient.

The detected optical signals are obtained conventionally by passing red and infrared light through a patient's blood perfused tissue, detecting the transmitted light which is modulated by the blood flow, and providing red and infrared detected optical signals that are preferably separately processed and optionally converted from analog to digital signals. The corresponding red and infrared digital optical signals are then processed in accordance with the present invention and the light modulation ratios are determined based on the resulting corrected transmittance pulse and used to calculate oxygen saturation.

Applicants have discovered that the detected optical signals can be processed and corrected in accordance with the present invention by using the frequency characteristics of the detected optical signal. The optical signals for a given wavelength corresponding to the pulsatile arterial blood flow have spectral components including a zero frequency at the background transmittance intensity level, a fundamental frequency at the frequency of the beating heart, and additional harmonic frequencies at multiples of the fundamental frequency. Noise, spurious signals, and motion artifact that appear in the detected optical signal have frequencies that spread across the spectrum. Transient changes to the background transmittance intensity appear as low frequency signals that are below the heart rate frequency.

In accordance with the invention, for each of the wavelengths of the light transmitted, the detected

optical signal is split into two portions. For one of the portions, the frequency domain corresponding to the frequency components below the range of the measured heart rate, including the background and any transient frequency components, is separated from the higher frequency components. Applicants have discovered that if the first domain is separated so that no phase shifting occurs relative to the other portion of the unfiltered detected signal, the first domain signal can be divided into the unfiltered signal, thereby to correct for changes in the pulsatile amplitude in the unfiltered signal portion on a continuous basis, for the background transmittance during steady state conditions, during artifactual blood volume changes and transient saturation transmittance changes. It may be appropriate to amplify the separated or filtered signal, the unfiltered signal, or the resulting quotient signal to obtain an adjusted signal having an appropriate amplitude and resolution for making the saturation determination.

Separation of the low frequency components may be realized in either the time domain or the frequency domain. In the time domain, the separation may occur by passing one portion of the analog detected optical signal through conventional electronic circuits such as low pass filters configured to avoid any phase shifting to obtain a filtered signal having only the background and low frequency components, and then passing the filtered signal and a portion of the unfiltered analog detected signal into dividing amplifiers to divide the low passed signal into the unfiltered signal in phase. This process results in a compensated optical signal that can be processed as if it were the actual detected optical signal to determine the relative maxima and minima of the detected pulses for the saturation calculations. Alternately, the detected optical signal may be digitized and processed using digital signal processing techniques to filter the detected signal and divide the filtered signal into the unfiltered detected signal.

Digital processing techniques also may be applied to process the detected optical signal in the frequency domain by the application of well-known Fourier Transforms. In this embodiment, a time-measure of the detected optical signal for a predetermined number of heartbeats is collected and transformed into its spectral components. The frequency components are then separated into two domains, the first domain including spectral components below the measured heart rate so that it includes the zero frequency spectral components of the background intensity and any gradual changes in the background intensity corresponding to the transient condition, and the second domain being above the first so that it includes the spectral components of the fundamental and higher order harmonics of the fundamental for the number of heartbeats in the sample. The separation must occur so that no phase shifting occurs in the first domain. Then, the filtered first domain spectral components can be transformed back into the time domain, into the background and changing background intensity, and divided into the unfiltered detected pulsatile waveform in phase thereby compensating for transient conditions in the unfiltered waveform. As the time-measure is updated to include the patient's current condition, the division of the unfiltered waveform by its low frequency components thus corrects the pulsatile amplitude for changes in the background transmittance on a continuous basis.

Thereafter, the oxygen saturation calculation can be based upon the compensated quotient waveform.

The apparatus of the present invention includes inputs for the detected optical signals, an analog to digital converter for converting the analog plethysmograph signal to the digital optical signals (unless the plethysmograph signals are provided in digital form), and a digital signal processing section for receiving the digital signals and processing the digital detected optical signal in accordance with the present invention, including a microprocessor, memory devices, buffers, software for controlling the microprocessor, and display devices.

In its context, the apparatus of the present invention is a part of an oximeter device which has the capability to detect the red and infrared light absorption. In the preferred embodiment, the apparatus of this invention is a part of the Nellcor N-200 oximeter which includes a 16 bit microprocessor manufactured by Intel Corporation, Model No. 8088, software for controlling the microprocessor to perform the conventional oximeter functions, and has structure and processing methods that are unrelated to the present invention, and therefore are not discussed herein.

The invention is described in detail in connection with the drawings in which

Fig. 1 is a block diagram of the apparatus of this invention and the apparatus associated with the present invention,

Fig. 2 is a detailed circuit schematic of the saturation preamplifier in the patient module of Fig. 1,

Figs. 3A and 3B are a detailed circuit schematic of the saturation analog front end circuit of Fig. 1,

Fig. 4 is a detailed circuit schematic of the LED drive circuit of Fig. 1,

Figs. 5A and 5B are a detailed circuit schematic of the analog to digital converter section of Fig. 1,

Figs. 6A, 6B, and 6C are a detailed circuit schematic of the digital signal processing section of Fig. 1,

and

Figs. 7a, 7b, 7c, 7d, 7e, and 7f are graphical representations of detected optical signals during steady state and transient conditions.

Referring to Fig. 1, the preferred embodiment of the present invention relates to the apparatus for processing the detected analog optical plethysmograph signal and comprises portions of analog to digital conversion section ("ADC converter") 1000 and digital signal processing section ("DSP") 2000, including the software for driving microprocessor 2040, which processes the digitized optical signals in accordance with the present invention to determine the oxygen saturation of hemoglobin in arterial blood. Associated with the invention, but not forming a part of the invention, is the apparatus for obtaining the detected analog optical signals from the patient that is part of or is associated with the commercially available Nellcor N-200 Pulse Oximeter. Such apparatus include plethysmograph sensor 100 for detecting optical signals including periodic optical pulses, patient module 200 for interfacing plethysmograph sensor 100 with saturation analog front end circuit 300, and saturation analog circuit 300 for processing the detected optical signals into separate red and infrared channels that can be digitized. The N-200 oximeter also includes LED drive circuit 600 for strobing the red and infrared LEDs in plethysmograph sensor 100 at the proper intensity to obtain a detected optical signal that is acceptable for processing, and various regulated power supplies (not shown) for driving or biasing the associated circuits, as well as ADC 1000 and DSP 2000, from line current or storage batteries.

The associated elements are straightforward circuits providing specified functions which are within the skill of the ordinary engineer to design and build. The associated elements are briefly described here, and reference is made to the corresponding detailed schematics in the Figures and circuit element tables set forth below, to place the apparatus of the present invention in its operating context in the preferred embodiment.

In the preferred embodiment, the invention requires two input signals, the two plethysmograph or detected optical signals at the first and second wavelengths (e.g., red and Infrared). More than two wavelengths may be used. If analog signals are provided, they must be within or be adjusted by, for example, offset amplifiers to be within the voltage input range for the ADC. In circumstances where the signals have been digitized already, they must be bit compatible with the digital signal processing devices, DSP.

The plethysmograph signal is obtained in a conventional manner for a non-invasive oximeter, typically by illuminating the patient's tissue with red and infrared light in an alternating fashion, for example, in the manner described above for the N-100 oximeter. Referring to Fig. 1, sensor circuit 100 has red LED 110 and infrared LED 120 connected in parallel, anode to cathode, so that the LED drive current alternately illuminates one LED and then the other LED. Circuit 100 also includes photodetector 130, preferably a photodiode, which detects the level of light transmitted through the patient's tissue, e.g., finger 140, as a single, analog optical signal containing both the red and infrared light plethysmographic, detected optical signal waveforms.

Referring to Figs. 1, and 2, patient module 200 includes preamplifier 210 for preamplifying the analog detected optical signal of photodetector 130. Preamplifier 210 may be an operational amplifier configured as a current to voltage converter, biased by a positive voltage to extend the dynamic range of the system, thereby converting the photocurrent of photodiode 130 into a usable voltage signal. Patient module 200 also includes leads for passing the LED drive voltages to LEDs 110 and 120.

Referring to Figs. 1, 3A and 3B, saturation analog front end circuit 300 receives the analog optical signal from patient module 200 and filters and processes the detected signal to provide separate red and infrared analog voltage signals corresponding to the detected red and infrared optical pulses. The voltage signal is passed through low pass filter 310 to remove unwanted high frequency components above, for example, 100 khz, AC coupled through capacitor 325 to remove the DC component, passed through high pass filter 320 to remove any unwanted low frequencies below, for example, 20 hertz, and passed through buffer 320 and passed through programmable gain stage 330 to amplify and optimize the signal level presented to synchronous detector 340.

Synchronous detector 340 removes any common mode signals present and splits the time multiplexed optical signal into two channels, one representing the red voltage signals and the other representing the infrared voltage signals. Each signal is then passed through respective filter chains having two 2-pole 20 hertz low pass filters 350 and 360, and offset amplifier 370 and 380. The filtered voltage signals now contain the signal information corresponding to the red and infrared detected optical signals. Additionally, circuits for use in preventing overdriving the amplifiers in saturation circuit 300 may be applied, for example, level-sensing circuits 312 and 314 (located before and after low pass filter 310 respectively) for indicating unacceptable LED drive current, and level sensing circuit 315 (located after programmable gain

amplifier 330) for indicating unacceptable input amplifier gain setting.

Referring to Figs. 1, 5A and 5B, ADC 1000 provides the analog to digital conversions required by the N-200 oximeter. The aforementioned two voltage signals, the red detected optical signal and the infrared detected optical signal from patient module 200, are input to ADC 1000. These signals are conventionally multiplexed and digitized by an expanded range 12-bit analog-to-digital conversion technique, yielding 16-bit resolution. The input signals are passed through multiplexor 1010 and buffer amplifier 1020. The converter stage includes offset amplifier 1030 and programmable gain circuitry 1040 which allows a portion of the signal to be removed and the remainder to be further amplified for greater resolution, sample and hold circuit 1050, comparator 1060, and 12-bit digital to analog converter 1080. The buffered signal is passed through offset amplifier 1030 to add a DC bias to the signal wherein a portion of the signal is removed and the balance is amplified by being passed through programmable gain circuitry 1040 to improve the resolution. The amplified signal is then passed through sample and hold circuit 1050, the output of which is fed to one input of comparator 1060. The other input of comparator 1060 is the output of digital to analog ("DAC") converter 1080 so that when the inputs to comparator 1060 are the same, the analog voltage at the sample and hold circuit is given the corresponding digital word in DAC converter 1080 which is then stored in an appropriate memory device as the digitized data for the sample and the next sample is sent to sample and hold circuit 1050 to be digitized.

Referring to Figs. 1, 4, 5A, 5B, 6A, 6B, and 6C, DAC 1080 also generates the sensor LED drive voltages, under the control of microprocessor 2040, using analog multiplexor 610, which separates the incoming analog signal into one of two channels for respectively driving the red and infrared LEDs, having respective sample and hold circuits 620 and 630, and LED driver circuit 640 for converting the respective analog voltage signals into the respective positive and negative bipolar current signals for driving LEDs 110 and 120.

Alternate techniques of converting the analog signals to digital signals could be used, for example, a 16-bit analog to digital converter.

Referring to Figs. 1, 6A, 6B and 6C, DSP 2000 controls all aspects of the signal processing operation including the signal input and output and intermediate processing. The apparatus includes 16-bit microprocessor 2040 and its associated support circuitry including data bus 10, random access memory (RAM) 2020, read only memory (ROM) 2030, a conventional LED display device 2010 (not described in detail), system timing circuit 2050 for providing the necessary clock synchronizing signals. In the preferred embodiment, microprocessor 2040 is a model 8088 microprocessor, manufactured by Intel Corporation, Santa Clara, California. Alternate microprocessors may be used, such as any of model nos. 8086, 80186, and 80286, also made by Intel Corporation.

The N-200 oximeter incorporating the present invention is designed to determine the oxygen saturation in one of two modes, an unintegrated mode wherein the oxygen saturation determination is made on the basis of pulses detected in the optical pulse signal that are determined to be optical pulses in accordance with conventional pulse detection techniques, and in an ECG synchronization mode wherein the determination is based on enhanced periodic data obtained by processing the detected optical signal and the ECG waveform of the patient in accordance with an invention that is not a part of the present invention.

The present invention applies to the calculation of saturation based on detecting maximum and minimum transmittance of two or more wavelengths, whether the determination is made pulse by pulse (the unintegrated mode) or based on an averaged or composite pulse that is updated with the occurrence of additional pulses to reflect the patient's actual condition (the ECG synchronized mode).

Interrupt programs control the collection and digitization of incoming optical signal data. As particular events occur, various software flags are raised which transfer operation to various routines that are called from a main loop processing routine.

The detected optical signal waveform is sampled at a rate of 57 samples per second. When the digitized red and infrared signals for a given portion of detected optical signals are obtained, they are stored in a buffer called DATBUF and a software flag indicating the presence of data is set.

This set flag calls a routine referred to as MUNCH, which processes each new digitized optical signal waveform sample to identify pairs of maximum and minimum amplitudes corresponding to a pulse. The MUNCH routine first queries whether or not there is ECG synchronization. If there is ECG synchronization, then the MUNCH routine obtains the enhanced composite pulse data in the ECG synchronization mode. Otherwise, MUNCH obtains the red and infrared optical signal sample stored in DATBUF, in the unintegrated mode. The determined maximum and minimum pairs are then sent to a processing routine for processing the pairs. Preferably, conventional techniques are used for evaluating whether a detected pulse pair is acceptable for processing as an arterial pulse and performing the saturation calculation, whether the pulse pair is obtained from DATBUF or from the enhanced composite pulse data.

The MUNCH routine takes the first coming pulse data and determines the maximum and minimum transmittance for each of the red and infrared detected optical signals, takes the second coming pulse data, and determines the relative maximum and minimum transmittance. The routine for processing the pairs applies the aforementioned frequency compensation techniques to the pulse data of each wavelength and determines the corrected transmittance for the pulse for each wavelength. Then the oxygen saturation can be determined using the corrected transmittance values for the detected pulses of the red and infrared optical signals.

The application of the present invention is demonstrated by the following, with reference to Figs. 7a, 7b, 7c, 7d, 7e, and 7f.

#### Example I

Figs. 7a and 7b show representative plethysmograph waveforms for a patient's steady state condition for the red and infrared detected optical signals.  $V_{maxr}(n)$  equals 1.01 volts, and  $V_{minr}(n)$  equals 1.00 volts, for  $n = 1, 2$ , and 3 pulses.  $V_{min}(n)$  is the detected optical signal minimum value at the minimum transmittance at the  $n$  pulse minimum. The modulation ratio for the maxima and minima red signal is

$$\frac{V_{maxr}(n)}{V_{minr}(n)} = \frac{1.01v}{1.00v} = 1.01$$

For the infrared wavelength,  $V_{maxi}(n) = 1.01v$  and  $V_{mini}(n) = 1.00v$  and the determined modulation ratio also is 1.01.

Using these determined modulation ratios in the formula for calculating the ratio  $R$  provides:

$$R = \frac{\ln [V_{maxr}(n)/V_{minr}(n)]}{\ln [V_{maxi}(n)/V_{mini}(n)]} = \frac{.01}{.01} = 1.00$$

A determined  $R = 1$  corresponds to an actual saturation value of about 81% when incorporated into the aforementioned saturation equation. A saturation of 81% corresponds to a healthy patient experiencing a degree of hypoxia for which some corrective action would be taken.

#### Example II

Figs. 7c and 7d correspond to representative plethysmographic waveforms for a patient during desaturation or decreasing saturation transient conditions for the red and infrared detected optical signals having optical pulses  $n = 1, 2$ , and 3. However, in this transient example it is known that at  $n = 1$ , the actual saturation of the patient is very close to that during the steady state conditions in the Example I. In this transient example, the detected values are as follows:

For both the red and infrared signals:

$t_{max}(1) = 1.0$  secs.  
 $t_{min}(1) = 1.2$  secs.  
 $t_{max}(2) = 2.0$  secs.  
 $t_{min}(2) = 2.2$  secs.  
 $t_{max}(3) = 3.0$  secs.  
 $t_{min}(3) = 3.2$  secs.

For the red optical signals:

$V_{maxr}(1) = 1.012v$   
 $V_{minr}(1) = 1.000v$   
 $V_{maxr}(2) = 1.002v$   
 $V_{minr}(2) = 0.990v$   
 $V_{maxr}(3) = 0.992v$

Vminr(3) = 0.980v

For the infrared optical signals:

Vmaxi(1) = 1.008v

Vmini(1) = 1.000v

5 Vmaxi(2) = 1.018v

Vmini(2) = 1.010v

Vmaxi(3) = 1.028v

Vmini(3) = 1.020v.

10 Calculating the oxygen saturation ratio R at n = 1, using the detected optical signals provides the following:

$$R = \ln[V_{\max r}(1)/V_{\min r}(1)]/\ln[V_{\max i}(1)/V_{\min i}(1)]$$

$$= \ln[1.012/1.000]/\ln[1.008/1.000]$$

$$= \ln[1.012]/\ln[1.008]$$

$$= .012/.008$$

15 = 1.5

Thus, the determined saturation ratio R of 1.5 based on the detected transmittance corresponds to a calculated oxygen saturation of about 65% for the patient, which corresponds to severe hypoxia in an otherwise healthy patient. This contrasts with the known saturation of about 81% and demonstrates the magnitude of the under-estimation of the oxygen saturation (over-estimation of desaturation) due to the distortion in transmittance of the red and infrared light caused by transient conditions.

20 The present invention corrects for the distorted maximum transmittance points of the detected red optical signal during transient conditions to obtain a corrected R value that corresponds to approximately the same R for the steady state conditions and the actual oxygen saturation of the patient.

25

### Example III

30 Figs. 7e and 7f correspond to representative plethysmographic waveforms for a patient during increasing saturation transient conditions for the red and infrared detected optical signals having optical pulses n = 1, 2, and 3. However, in this transient example it is known that at n = 1, the actual saturation of the patient is very close to that during the conditions in the steady state Example I. In this transient example, the detected values are as follows:

For both the red and infrared signals:

35 tmax(1) = 1.0 secs.

tmin(1) = 1.2 secs.

tmax(2) = 2.0 secs.

tmin(2) = 2.2 secs.

tmax(3) = 3.0 secs.

40 tmin(3) = 3.2 secs.

For the red optical signals:

Vmaxr(1) = 1.008v

Vminr(1) = 1.000v

Vmaxr(2) = 1.018v

45 Vminr(2) = 1.010v

Vmaxr(3) = 1.028v

Vminr(3) = 1.020v

For the infrared optical signals: Vmaxi(1) = 1.012v

Vmini(1) = 1.000v

50 Vmaxi(2) = 1.002v

Vmini(2) = .990v

Vmaxi(3) = .992v

Vmini(3) = .980v.

55 Calculating the oxygen saturation ratio R at n = 1, using the detected optical signals provides the following:  $R = \ln[V_{\max r}(1)/V_{\min r}(1)]/\ln[V_{\max i}(1)/V_{\min i}(1)]$

$$= \ln[1.008/1.000]/\ln[1.012/1.000]$$

$$= \ln[1.008]/\ln[1.012]$$

$$= .008/.012$$

= .667

Thus, the determined saturation R of .667 corresponds to a calculated oxygen saturation of about 95% for the patient which corresponds to a satisfactorily oxygenated patient breathing room air. This contrasts with the known saturation of about 81% and demonstrates the magnitude of the over-estimation of saturation due to the distortion in transmittance of the red and infrared light caused by transient conditions.

The present invention corrects for the distorted maximum transmittance points of the detected red optical signal during transient conditions to obtain a corrected R that value corresponds to approximately the same R for the steady state conditions and the actual oxygen saturation of the patient.

#### Example IV

Figs. 7c and 7d also correspond to representative plethysmographic waveforms for a patient during desaturation or decreasing saturation transient conditions for the red and infrared detected optical signals having optical pulses  $n = 1, 2$ , and  $3$ . However, in this transient example it is known that at  $n = 2$ , the actual saturation of the patient is very close to that during the steady state conditions in the Example I. In this transient example, the detected values are as follows:

For both the red and infrared signals:

$t_{max}(1) = 1.0$  secs.

$t_{min}(1) = 1.2$  secs.

$t_{max}(2) = 2.0$  secs.

$t_{min}(2) = 2.2$  secs.

$t_{max}(3) = 3.0$  secs.

$t_{min}(3) = 3.2$  secs.

For the red optical signals:

$V_{maxr}(1) = 1.022v$

$V_{minr}(1) = 1.008v$

$V_{maxr}(2) = 1.012v$

$V_{minr}(2) = 0.998v$

$V_{maxr}(3) = 1.002v$

$V_{minr}(3) = 0.988v$

For the infrared optical signals:

$V_{maxi}(1) = 1.002v$

$V_{mini}(1) = 0.992v$

$V_{maxi}(2) = 1.012v$

$V_{mini}(2) = 1.002v$

$V_{maxi}(3) = 1.022v$

$V_{mini}(3) = 1.012v$

Calculating the oxygen saturation ratio R at  $n = 2$ , using the detected optical signals provides the following:

$$R = \ln[V_{maxr}(2)/V_{minr}(2)]/\ln[V_{maxi}(2)/V_{mini}(2)]$$

$$= \ln[1.012/0.998]/\ln[1.012/1.002]$$

$$= .01393/.0099$$

$$= 1.4$$

Thus, the determined saturation ratio R of 1.4 based on the detected transmittance corresponds to a calculated oxygen saturation of about 51% for the patient, which corresponds to severe hypoxia in an otherwise healthy patient. This contrasts with the known saturation of about 81% and demonstrates the magnitude of the under-estimation of the oxygen saturation (over-estimation of desaturation) due to the distortion in transmittance of the red and infrared light caused by transient conditions.

The present invention corrects for the distorted minimum transmittance points of the detected red optical signal during transient conditions to obtain a corrected R value that corresponds to approximately the same R for the steady state conditions and the actual oxygen saturation of the patient.

#### Example V

Figs. 7e and 7f also correspond to representative plethysmographic waveforms for a patient during increasing saturation transient conditions for the red and infrared detected optical signals having optical pulses  $n = 1, 2$ , and  $3$ . However, in this transient example it is known that at  $n = 2$ , the actual saturation of the patient is identical to that during the conditions in the steady state example. In this transient example,  
 5 the detected values are as follows:

For both the red and infrared signals:

$t_{\max}(1) = 1.0$  secs.  
 $t_{\min}(1) = 1.2$  secs.  
 $t_{\max}(2) = 2.0$  secs.  
 10  $t_{\min}(2) = 2.2$  secs.  
 $t_{\max}(3) = 3.0$  secs.  
 $t_{\min}(3) = 3.2$  secs.

For the red optical signals:

$V_{\max r}(1) = 1.002v$   
 15  $V_{\min r}(1) = 0.992v$   
 $V_{\max r}(2) = 1.012v$   
 $V_{\min r}(2) = 1.002v$   
 $V_{\max r}(3) = 1.022v$   
 $V_{\min r}(3) = 1.012v$

20 For the infrared optical signals:

$V_{\max i}(1) = 1.022v$   
 $V_{\min i}(1) = 1.008v$   
 $V_{\max i}(2) = 1.012v$   
 $V_{\min i}(2) = .998v$   
 25  $V_{\max i}(3) = 1.002v$   
 $V_{\min i}(3) = .988v$

Calculating the oxygen saturation ratio  $R$  at  $n = 2$ , using the detected optical signals provides the following:

$R = \ln[V_{\max r}(2)/V_{\min r}(2)]/\ln[V_{\max i}(2)/V_{\min i}(2)]$   
 30  $= \ln[1.012/1.002]/\ln[1.012/.988]$   
 $= .713$

Thus, the determined saturation  $R$  of .713 corresponds to a calculated oxygen saturation of about 92% for the patient which corresponds to a mildly hypoxic patient breathing room air. This contrasts with the known saturation of about 81% and demonstrates the magnitude of the over-estimation of saturation due to the distortion in transmittance of the red and infrared light caused by transient conditions.  
 35

The present invention corrects the distorted minimum transmittance points of the detected red optical signal during transient conditions to obtain a corrected  $R$  value that corresponds to approximately the same  $R$  for the steady state conditions and the actual oxygen saturation of the patient.

40

45

50

55

Circuit Tables

|    | <u>REF #</u> | <u>CHIP</u> | <u>MFR PART #</u> | <u>Manufacturer</u>       | <u>DESCRIPTION OF CHIP</u> |
|----|--------------|-------------|-------------------|---------------------------|----------------------------|
| 5  | FIG. 2       |             |                   |                           |                            |
|    | 210          | U2          | LF442             | NATIONAL<br>SEMICONDUCTOR | DUAL LOW POWER OP AMP      |
|    | FIG. 3.      |             |                   |                           |                            |
|    | 312          | U27         | LF444             | NATIONAL<br>SEMICONDUCTOR | QUAD JFET OP AMP           |
| 10 | 312          | U28         | LP365N            | NATIONAL<br>SEMICONDUCTOR | QUAD VOLTAGE COMPARATOR    |
|    | 310          | U27         | LF444             | NATIONAL<br>SEMICONDUCTOR | QUAD JFET OP AMP           |
|    | 320          | U27         | LF444             | NATIONAL<br>SEMICONDUCTOR | QUAD JFET OP AMP           |
| 15 | 330          | U44         | MP7524LN          | MICROPOWER                | 8-BIT DAC                  |
|    | 330          | U32         | LF444             | NATIONAL<br>SEMICONDUCTOR | QUAD JFET OP AMP           |
|    | 330          | U32         | LF444             | NATIONAL<br>SEMICONDUCTOR | QUAD JFET OP AMP           |
| 20 | 315          | U20         | LP365N            | NATIONAL<br>SEMICONDUCTOR | QUAD VOLTAGE COMPARATOR    |
|    | 340          | U32         | LF444             | NATIONAL<br>SEMICONDUCTOR | QUAD JFET OP AMP           |
| 25 | 340          | U14         | DG243CJ           | SILICONIX<br>INCORPORATED | ANALOG SWITCH              |
|    | 340          | U7          | LF444             | NATIONAL<br>SEMICONDUCTOR | QUAD JFET OP AMP           |
|    | 340          | U13         | LF444             | NATIONAL<br>SEMICONDUCTOR | QUAD JFET OP AMP           |
| 30 | 350          | U7          | LF444             | NATIONAL<br>SEMICONDUCTOR | QUAD JFET OP AMP           |
|    | 360          | U13         | LF444             | NATIONAL<br>SEMICONDUCTOR | QUAD JFET OP AMP           |
|    | 370          | U7          | LF444             | NATIONAL<br>SEMICONDUCTOR | QUAD JFET OP AMP           |
| 35 | 380          | U13         | LF444             | NATIONAL<br>SEMICONDUCTOR | QUAD JFET OP AMP           |
|    | 340          | U19         | DG211CJ           | SILICONIX<br>INCORPORATED | CMOS ANALOG SWITCH         |
| 40 | FIG. 4       |             |                   |                           |                            |
|    | 640          | U19         | DG211CJ           | SILICONIX<br>INCORPORATED | CMOS ANALOG SWITCH         |
|    | 640          | U32         | LF444             | NATIONAL<br>SEMICONDUCTOR | QUAD JFET OP AMP           |
| 45 | FIG. 5       |             |                   |                           |                            |
|    | 1010         | U24         | DG528CK           | SILICONIX<br>INCORPORATED | OCTAL ANALOG SWITCH        |
|    | 1020         | U25         | LF444             | NATIONAL<br>SEMICONDUCTOR | QUAD JFET OP AMP           |
| 50 | 1030         | U25         | LF444             | NATIONAL<br>SEMICONDUCTOR | QUAD JFET OP AMP           |
|    | 1040         | U38         | AD7524LN          | ANALOG DEVICES            | DAC                        |

55

|    |        |     |               |                 |                               |
|----|--------|-----|---------------|-----------------|-------------------------------|
|    | 1040   | U42 | 74HC374       | TEXAS           | HIGH SPEED CMOS               |
|    |        |     |               | INSTRUMENTS     |                               |
| 5  | 1040   | U37 | LF442N        | NATIONAL        | LOW POWER OP AMP              |
|    |        |     |               | SEMICONDUCTOR   |                               |
|    | 1050   | U36 | LF398N        | NATIONAL        | SAMPLE & HOLD OP AMP          |
|    |        |     |               | SEMICONDUCTOR   |                               |
|    | 1060   | U29 | LM211P        | TEXAS           | LOW OFFSET VOLTAGE COMPARATOR |
|    |        |     |               | INSTRUMENTS     |                               |
| 10 | 1080   | U43 | AD7548KN      | ANALOG DEVICES  | CMOS 12-BIT DAC               |
|    | 1080   | U31 | LF411ACN      | NATIONAL        | LOW OFFSET OP AMP             |
|    |        |     |               | SEMICONDUCTOR   |                               |
|    | 1080   | U25 | LF444         | NATIONAL        | QUAD JFET OP AMP              |
|    |        |     |               | SEMICONDUCTOR   |                               |
| 15 | 610    | U18 | DG528CK       | SILICONIX       | OCTAL ANALOG SWITCH           |
|    |        |     |               | INCORPORATED    |                               |
|    | 620    | U11 | LF444         | NATIONAL        | QUAD JFET OP AMP              |
|    |        |     |               | SEMICONDUCTOR   |                               |
|    | 630    | U11 | LF444         | NATIONAL        | QUAD JFET OP AMP              |
|    |        |     |               | SEMICONDUCTOR   |                               |
| 20 | FIG. 6 |     |               |                 |                               |
|    |        | U2  | 82C84A-2      | NEC             | CMOS 8 MHZ CLOCK GENERATOR    |
|    |        | U1  | 74HC74        | TEXAS           | HIGH SPEED CMOS               |
|    |        |     |               | INSTRUMENTS     |                               |
|    |        | U1  | 74HC74        | TEXAS           | HIGH SPEED CMOS               |
|    |        |     |               | INSTRUMENTS     |                               |
| 25 | 2040   | U8  | MSM80C88RS-2  | OKI ELECTRIC    | CPU 8MHZ, 125ns               |
|    |        | U3  | 74HC74        | TEXAS           | HIGH SPEED CMOS               |
|    |        |     |               | INSTRUMENTS     |                               |
|    |        | U33 | 74HC374       | TEXAS           | HIGH SPEED CMOS               |
|    |        |     |               | INSTRUMENTS     |                               |
| 30 |        | U9  | 74HC04        | TEXAS           | HIGH SPEED CMOS               |
|    |        |     |               | INSTRUMENTS     |                               |
|    |        | U3  | 74HC74        | TEXAS           | HIGH SPEED CMOS               |
|    |        |     |               | INSTRUMENTS     |                               |
| 35 |        | U9  | 74HC04        | TEXAS           | HIGH SPEED CMOS               |
|    |        |     |               | INSTRUMENTS     |                               |
|    |        | U19 | 74HC00        | TEXAS           | HIGH SPEED CMOS               |
|    |        |     |               | INSTRUMENTS     |                               |
|    |        | U9  | 74HC04        | TEXAS           | HIGH SPEED CMOS               |
|    |        |     |               | INSTRUMENTS     |                               |
| 40 | 2030   | U21 | MBM27C512-25  | FUJITSU LIMITED | CMOS 64K X 8 ROM              |
|    | 2020   | U15 | DS1242        | DALLAS          | CMOS 32K X 8 RAM              |
|    |        |     |               | SEMICONDUCTOR   |                               |
|    |        | U23 | 74HC138       | TEXAS           | HIGH SPEED CMOS               |
|    |        |     |               | INSTRUMENTS     |                               |
| 45 |        | U17 | 74HC138       | TEXAS           | HIGH SPEED CMOS               |
|    |        |     |               | INSTRUMENTS     |                               |
|    |        | U19 | 74HC00        | TEXAS           | HIGH SPEED CMOS               |
|    |        |     |               | INSTRUMENTS     |                               |
|    |        | U19 | 74HC00        | TEXAS           | HIGH SPEED CMOS               |
|    |        |     |               | INSTRUMENTS     |                               |
| 50 |        | U16 | 82C51A        | OKI ELECTRIC    | CMOS UART                     |
|    |        | U22 | MSM82C59A-2RS | OKI ELECTRIC    | CMOS INTERRUPT CONTROLLER     |
|    | 2050   | U34 | MSM82C53-2    | OKI ELECTRIC    | CMOS TRIPLE TIMER             |
|    | 2050   | U38 | MSM82C53-2    | OKI ELECTRIC    | CMOS TRIPLE TIMER             |
| 55 | 2050   | U9  | 74HC04        | TEXAS           | HIGH SPEED CMOS               |

|    |      |     |         |             |                 |
|----|------|-----|---------|-------------|-----------------|
|    |      |     |         | INSTRUMENTS |                 |
|    | 2050 | U39 | 74HC393 | TEXAS       | HIGH SPEED CMOS |
| 5  |      |     |         | INSTRUMENTS |                 |
|    | 2050 | U35 | D2732A  | INTEL       | 4096 X 8 ROM    |
|    |      |     |         | CORPORATION |                 |
|    | 2050 | U40 | 74HC374 | TEXAS       | HIGH SPEED CMOS |
| 10 |      |     |         | INSTRUMENTS |                 |
|    | 2050 | U28 | 74HC374 | TEXAS       | HIGH SPEED CMOS |
|    |      |     |         | INSTRUMENTS |                 |

15

**Claims**

1. A method for detecting and processing arterial pulses of a patient during transient conditions characterized by:
- 20 passing a first light frequency through the patient's tissue and detecting a first optical signal corresponding to changes in the transmittance of the first frequency including periodic transmittance changes related to the patient's beating heart, aperiodic transmittance changes unrelated to the beating heart, background transmittance, and transient background transmittance changes at frequencies below the heart rate;
- 25 passing a second light frequency through the patient's tissue and detecting a second optical signal corresponding to changes in the transmittance of the second frequency including periodic transmittance changes related to the patient's beating heart, aperiodic transmittance changes unrelated to the beating heart, background transmittance, and transient background transmittance changes at frequencies below the heart rate; and, for each of the first and second detected optical signals;
- 30 processing the detected optical signal to obtain a filtered signal substantially comprising the background transmittance and transient background transmittance components of the detected optical signal below the heart rate frequency; and
- adjusting the detected optical signal by dividing the detected optical signal by the filtered signal in phase, thereby providing a compensated optical signal.
2. The method of claim 1 further characterized by calculating oxygen saturation of the patient's arterial
- 35 blood flow by processing the compensated first optical signal and the compensated second optical signal to detect the maximum or minimum transmittances in the compensated signals for use in calculating saturation.
3. The method of claim 2 characterized in that processing each of the first and second optical signals further comprises passing the optical signal through a low pass filter to remove substantially all of the
- 40 frequency components above the background transmittance and transient background transmittance frequency components so that the filtered optical signal remains in phase with the unfiltered detected optical signal.
4. The method of claim 2 characterized in that processing each of the first and second optical signals is further characterized by transforming the detected first and second optical signals into the frequency
- 45 domain, separating from the transformed frequency spectrum the low frequencies spectral components below the heart rate of the first and second light frequencies corresponding to the background transmittance and the transient background transmittance changes, and transforming the low frequency spectrum back into the time domain as the filtered signal.
5. Apparatus for compensating distortion in transmittance caused by transient conditions in a patient's
- 50 plethysmograph waveform having periodic changes related to the patients beating heart, aperiodic changes unrelated to the beating heart, background transmittance, and transient background transmittance changes at frequencies below the heart rate for use in an oximeter device, characterized by:
- means for receiving a detected optical signal corresponding to the transmittance of a first and second light frequency passing through the patient's tissue;
- 55 filter means for separating the frequency components that are below the fundamental heart rate, thereby providing a filtered signal; and
- dividing means for dividing the detected optical signal by the filtered signal in phase, thereby providing a compensated optical signal.

6. The apparatus of claim 5 further characterized by means for calculating oxygen saturation using the compensated optical signal.

7. The apparatus of claim 5 or 6 characterized in that the filter means is further characterized by a low pass filter circuit configured to pass all frequencies below the fundamental heart rate in phase with the  
5 unfiltered signal.

8. The apparatus of claim 5 or 6 characterized in that the filter means is further characterized by:  
means for transforming the first optical signal into the frequency domain;  
spectral filter means for separating the spectral components below the fundamental heart rate into a filtered  
10 spectrum; and  
means for transforming the filtered spectrum back into the time domain, thereby forming the first filtered  
signal.

9. The apparatus of claims 5 to 8 characterized in that the filter means and dividing means are further  
characterized by a digital microprocessor device and said apparatus further characterized by means for  
digitizing the detected optical signal into data acceptable for processing by the microprocessor device.

10. Apparatus for compensating distortion in transmittance caused by transient conditions in a patient's  
15 plethysmograph waveform having periodic changes related to the patients beating heart, aperiodic changes  
unrelated to the beating heart, background transmittance, and transient background transmittance changes  
at frequencies below the heart rate for use in an oximeter device, characterized by:  
means for receiving a first and second optical signals corresponding to the transmittance of first and second  
20 light frequencies passing through the patient's tissue;  
first filter means for separating the frequency components of the first optical signal that are below the  
fundamental heart rate, thereby providing a first filtered signal;  
second filter means for separating the frequency components of the second optical signal that are below  
the fundamental heart rate, thereby providing a second filtered signal;  
25 a first dividing means for dividing the first optical signal by the first filtered signal in phase, thereby  
providing a compensated first optical signal; and  
a second dividing means for dividing the second optical signal by the second filtered signal in phase,  
thereby providing a compensated second optical signal.

11. The apparatus of claim 10 further characterized by means for calculating oxygen saturation using  
30 the first and second corrected compensated signals.

12. The apparatus of claim 10 or 11 characterized in that the first and second filter means are further  
characterized by a first and second low pass filter circuit configured to pass all frequencies below the  
fundamental heart rate in phase with the unfiltered signal.

13. The apparatus of claim 10 or 11 characterized in that the first and second filter means are further  
35 characterized by:  
first means for transforming the first optical signal into the frequency domain;  
first spectral filter means for separating the spectral components below the fundamental heart rate into a  
first filtered spectrum;  
means for transforming the filtered spectrum back into the time domain, thereby forming the first filtered  
40 signal;  
second means for transforming the second optical signal into the frequency domain;  
second spectral filter means for separating the spectral components below the fundamental heart rate into a  
second filtered spectrum; and  
means for transforming the second filtered spectrum back into the time domain, thereby forming the second  
45 filtered signal.

14. The saturation of claims 10 to 13 characterized in that the first and second filter means and dividing  
means are further characterized by a digital microprocessor device and said apparatus is further character-  
ized by means for digitizing the first and second optical into data acceptable for processing by the  
microprocessor device.

50

55

FIG. 1








FIG. 3A




**FIG. 3B**

70 FIG. 3A



|       | +15 | -15 | +5 | AGND | DGND |
|-------|-----|-----|----|------|------|
| LP345 | 4   | 19  |    |      | 16   |
| LS444 | 4   | 11  |    |      |      |
| DS211 | 13  | 4   | 12 | 5    |      |
| DG203 | 11  | 14  | 12 | 13   |      |
| 7324  |     |     |    | 3    |      |

FIG. 5A



TO FIG. 5B



|      | +15 | -15 | +5 | Age | Score |
|------|-----|-----|----|-----|-------|
| 528  | 14  | 4   |    | 15  |       |
| 398  | 1   | 4   |    |     |       |
| 442  | 8   | 4   |    |     |       |
| 444  | 4   | 11  |    |     |       |
| 374  |     |     | 20 |     | 10    |
| 211  | 8   | 4   |    |     | 1     |
| 417  | 7   | 4   |    |     |       |
| 244  |     |     | 20 |     | 10    |
| 7548 | 18  |     |    | 2   | 3     |
| 7520 | 14  |     |    | 3   |       |

FIG. 6A









FIG. 6B







19



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

11 Publication number:

0 335 356  
A3

12

## EUROPEAN PATENT APPLICATION

21 Application number: 89105501.4

51 Int. Cl.<sup>5</sup>: A61B 5/00

22 Date of filing: 29.03.89

30 Priority: 30.03.88 US 175115

43 Date of publication of application:  
04.10.89 Bulletin 89/40

84 Designated Contracting States:  
AT BE CH DE FR GB LI LU NL

88 Date of deferred publication of the search report:  
29.08.90 Bulletin 90/35

71 Applicant: NELLCOR INCORPORATED  
25495 Whitesell Street

Hayward California 94545(US)

72 Inventor: Stone, Robert T.  
1028 Helena Drive  
Sunnyvale California 94087(US)  
Inventor: Briggs, Deborah A.  
2426 Talavera Drive  
San Ramon California 94583(US)


74 Representative: Vossius & Partner  
Siebertstrasse 4 P.O. Box 86 07 67  
D-8000 München 86(DE)

54 Method and apparatus for calculating arterial oxygen saturation based on plethysmographs including transients.

57 A method and apparatus for improving the calculation of oxygen saturation by non-invasive pulse oximeters during transient conditions. Transient conditions introduce artifactual errors into the detected optical signal because of changes in transmittance of the light with localized blood volume changes and as the average background oxygen saturation level of

the patient's blood changes. The invention relates to correcting the detected optical pulses by selective frequency filtering and compensating the detected optical signal using the filtered signal to provide accurate estimates of oxygen saturation during transient conditions.

FIG. 1





European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number

EP 89 10 5501

| DOCUMENTS CONSIDERED TO BE RELEVANT   |   |  |   |
|---|---|--|---|
| Category  | Citation of document with indication, where appropriate, of relevant passages   | Relevant to claim                              | CLASSIFICATION OF THE APPLICATION (Int. Cl.4) |
| A   | WO-A-8 801 149 (PHYSIO CONTROL CORPORATION)<br>* abstract; page 14, line 22 - page 20, line 33; figures 1,8-11 *                  | 1-14   | A 61 B 5/00                                   |
| A   | WO-A-8 203 322 (BIOX TECHNOLOGY INC.)<br>* abstract; page 5, line 6 - page 8, line 23; figure 1 *; & US - A - 44 07290 (Cat. D)   | 1,5,10   |   |
| A,D   | EP-A-0 102 816 (NELLCOR INCORPORATION)<br>* page 7, line 33 - page 8, line 20; page 10, line 36 - page 12, line 38; figures 1,2 * | 1,5,10   |   |
|   |   |  | TECHNICAL FIELDS SEARCHED (Int. Cl.4)         |
|   |   |  | A 61 B 5/00<br>G 01 N 21/00                   |
| The present search report has been drawn up for all claims  |   |  |   |
| Place of search<br>BERLIN   |   | Date of completion of the search<br>08-06-1990 | Examiner<br>WEIHS J.A.                        |
| <b>CATEGORY OF CITED DOCUMENTS</b><br>X : particularly relevant if taken alone<br>Y : particularly relevant if combined with another document of the same category<br>A : technological background<br>O : non-written disclosure<br>P : intermediate document<br>T : theory or principle underlying the invention<br>E : earlier patent document, but published on, or after the filing date<br>D : document cited in the application<br>L : document cited for other reasons<br>& : member of the same patent family, corresponding document |   |  |   |